NEWS
CBT recently developed and validated in vitro methods of the skin and ocular irritation assessment using human reconstructed 3D epithelium according to the approved methods in the OECD Guidelines 439 and 492, respectively.
CBT developed the organoid mammary gland 3D patient cancer model and developed a method of the high throughput assessment of the efficacy of the panel of anticancer drugs in this patient-derived tumors which can be used for the precision medicine to select the most efficacious treatment for a specific patient.
​
​
CBT recently completed entire IND packages for 3 drugs which are now in Phase 1-3 clinical trials in the USA and Australia. The clinical trials are also supported by CBT analytical work and PK analysis.
CBT recently developed new methods for several viral antibody titers and cell-based neutralization assays in rabbit and monkey plasma and serum. In addition, a method for ADA measurement in dog plasma was developed and successfully implemented using the MSD platform.
CBT developed new highly sensitive non-invasive methods for calprotectin and lactoferrin evaluation in non-human primate feces and cytokine methods in mouse blood and feces as biomarkers of gastro-intestinal inflammation (including for infections, bowel irritation and acute radiation syndrome).
CBT developed and validated new highly sensitive multiplex cytokine assays in non-human primate, dog, minipig, mice, and human plasma using the MSD chemiluminescent platform.
​​​​